Achieving PSA < 0.2 ngml before Radiation Therapy Is a Strong Predictor of Treatment Success in Patients with High-Risk Locally Advanced Prostate Cancer

المؤلفون المشاركون

Hara, Noboru
Kazama, Akira
Saito, Toshihiro
Takeda, Keisuke
Kobayashi, Kazuhiro
Tanikawa, Toshiki
Kanemoto, Ayae
Ayukawa, Fumio
Matsumoto, Yasuo
Sugita, Tadashi
Tomita, Yoshihiko

المصدر

Prostate Cancer

العدد

المجلد 2019، العدد 2019 (31 ديسمبر/كانون الأول 2019)، ص ص. 1-6، 6ص.

الناشر

Hindawi Publishing Corporation

تاريخ النشر

2019-10-17

دولة النشر

مصر

عدد الصفحات

6

التخصصات الرئيسية

الأمراض
الطب البشري

الملخص EN

Background.

To predict long-term treatment outcome of radiation therapy (RT) plus androgen deprivation therapy (ADT) for high-risk locally advanced prostate cancer.

Methods.

In total, 204 patients with the National Comprehensive Cancer Network (NCCN) high risk locally advanced prostate cancer (PSA > 20 ng/ml, Gleason score ≧ 8, clinical T stage ≧ 3a) were treated with definitive RT with ADT.

Median follow up period was 113 months (IQR: 95–128).

Median neoadjuvant ADT and total ADT duration were 7 months (IQR: 6–10) and 27 months (IQR: 14–38), respectively.

Results.

PSA recurrence-free survival (PSA-RFS), cancer specific survival (CSS), and overall survival (OS) rates at 5 years were 84.1%, 98.5%, and 93.6%, respectively, and 67.9%, 91.2%, and 78.1%, respectively, at 10 years.

Pre-RT PSA less than 0.2 ng/ml was associated with superior outcomes of PSA-RFS (HR = 0.42, 95% CI: 0.25–0.70, p=0.001), CSS (HR = 0.27, 95% CI: 0.09–0.82, p=0.013), and OS (HR = 0.48, 95% CI: 0.26–0.91, p=0.021).

On multivariate analysis, age (≥70 y.o.) and pre-RT PSA (≥0.2 ng/ml) were factors predictive of poorer OS (p=0.032) , but iPSA, T stage, Gleason score, number of NCCN high-risk criteria, a combination with anti-androgen therapy and neoadjuvant ADT duration were not predictive of treatment outcome.

Conclusion.

In patient with high-risk prostate cancer, RT plus ADT achieved good oncologic outcomes.

PSA < 0.2 ng/ml before radiation therapy is a strong independent predictor for long overall survival.

نمط استشهاد جمعية علماء النفس الأمريكية (APA)

Kazama, Akira& Saito, Toshihiro& Takeda, Keisuke& Kobayashi, Kazuhiro& Tanikawa, Toshiki& Kanemoto, Ayae…[et al.]. 2019. Achieving PSA < 0.2 ngml before Radiation Therapy Is a Strong Predictor of Treatment Success in Patients with High-Risk Locally Advanced Prostate Cancer. Prostate Cancer،Vol. 2019, no. 2019, pp.1-6.
https://search.emarefa.net/detail/BIM-1206797

نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)

Kazama, Akira…[et al.]. Achieving PSA < 0.2 ngml before Radiation Therapy Is a Strong Predictor of Treatment Success in Patients with High-Risk Locally Advanced Prostate Cancer. Prostate Cancer No. 2019 (2019), pp.1-6.
https://search.emarefa.net/detail/BIM-1206797

نمط استشهاد الجمعية الطبية الأمريكية (AMA)

Kazama, Akira& Saito, Toshihiro& Takeda, Keisuke& Kobayashi, Kazuhiro& Tanikawa, Toshiki& Kanemoto, Ayae…[et al.]. Achieving PSA < 0.2 ngml before Radiation Therapy Is a Strong Predictor of Treatment Success in Patients with High-Risk Locally Advanced Prostate Cancer. Prostate Cancer. 2019. Vol. 2019, no. 2019, pp.1-6.
https://search.emarefa.net/detail/BIM-1206797

نوع البيانات

مقالات

لغة النص

الإنجليزية

الملاحظات

Includes bibliographical references

رقم السجل

BIM-1206797